Details of the Drug

General Information of Drug (ID: DMWKSFY)

Drug Name
GSK3511294
Synonyms depemokimab
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
chronic rhinosinusitis with nasal polyps CA0A Phase 3 [2]
Eosinophilic granulomatosis with polyangiitis 4A44.A2 Phase 3 [3]
Hypereosinophilic syndrome 2A20.3 Phase 3 [4]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DP8AS7
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-5 (IL5) TTPREZD IL5_HUMAN Not Available [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Asthma
ICD Disease Classification CA23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-5 (IL5) DTT IL5 6.51E-01 -0.02 -0.11
Interleukin-5 (IL5) DTT IL5 1.71E-04 0.12 0.71
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05243680) A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05281523) A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis). U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05263934) A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT05334368) A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES). U.S.National Institutes of Health.
5 A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.